SAB Biotherapeutics’ COVID-19 antibody OK’d for Phase 3 trial
SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform, announced on Jan. 24 that its SAB-185 antibody candidate for COVID-19 treatment has […]
SAB Biotherapeutics’ COVID-19 antibody OK’d for Phase 3 trial Read More »










